Numinus has received approvals from Health Canada and the Institutional Ethics Review Board VANCOUVER, BC, Jan. 19, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has completed key steps to prepare to enroll participants at its clinics participating in “A multi-site open-label extension…


Previous articleTwo thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
Next articlePsychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II